Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases (REPRO-MICI)

May 18, 2026 updated by: University Hospital, Grenoble
Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • La Tronche, France, 38700
        • Grenoble Alpes University Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with IBD in severe relapse requiring hospitalisation for immunosuppressive therapy or endoscopy for relapse.

Description

Inclusion Criteria:

  • Men and women over 18
  • Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up
  • Patient not objecting to the REPRO-MICI study

Exclusion Criteria:

  • Patients protected by law (pregnant or breast-feeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalised under duress).
  • Patients with positive HIV, HBV or HCV serology.
  • Patients with a positive ELISPOT with no history of treatment for latent tuberculosis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparaison of reduction of concentration of inflammatory cytokines and chemokines in cells treated by oxygen microbubbles vs cells not treated
Time Frame: up to 2 years
Validation of inhibition of the production of inflammatory cytokines and chemokines by the monocytes treated by oxygen microbubbles
up to 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparaison of tissue factor expression at the membrane of monocytes treated by microbubbles vs monocytes not treated
Time Frame: up to 2 years
Inhibition of tissue factor expression at the membrane of treated monocytes
up to 2 years
Comparaison of glucose metabolism rate in monocytes treated bu microbubbles vs not treated cells
Time Frame: up to 2 years
Modulation of glucose metabolism in treated monocytes
up to 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Grenoble

Collaborators

Institute for Advanced Biosciences (IAB), Grenoble

Investigators

  • Principal Investigator: Marianne HUPE, MD PhD, Grenoble Alpes University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

April 30, 2028

Study Completion (Estimated)

July 31, 2028

Study Registration Dates

First Submitted

January 13, 2025

First Submitted That Met QC Criteria

April 17, 2025

First Posted (Actual)

April 25, 2025

Study Record Updates

Last Update Posted (Actual)

May 19, 2026

Last Update Submitted That Met QC Criteria

May 18, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 38RC24.0363

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammatory Bowel Disease (IBD)

Clinical Trials on Blood test 4 EDTA tubes

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe